Corcept Therapeutics News

Corcept Therapeutics(CORT.US) Officer Sells US$187.9K in Common Stock

$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 7,227 shares of common stock on May 9, 2024 at an average price of $26 for a total value of $187.9K.Source: Announcement What is statem

Futu NewsMay 13 21:13

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 1.35 Million in Common Stocks

SEC FILLINGS DISCLOSED/ May 13, $Corcept Therapeutics(CORT.US)$ Officer Maduck Sean intends to sell 50,000 shares of its common stock on May 13, with a total market value of approximately $1.35 millio

Futu NewsMay 13 11:29

10 Health Care Stocks With Whale Alerts In Today's Session

Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.

BenzingaMay 9 12:35

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 127K in Common Stocks

SEC FILLINGS DISCLOSED/ May 9, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on May 9, with a total market value of approximately $127K.

Futu NewsMay 9 11:38

Corcept Therapeutics(CORT.US) Officer Sells US$281.58K in Common Stock

$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 10,830 shares of common stock on May 2, 2024 at an average price of $26 for a total value of $281.58K.Source: Announcement What is stat

Futu NewsMay 6 20:03

Corcept Therapeutics(CORT.US) Director Sells US$50,798 in Common Stock

$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of common stock on May 1, 2024 at an average price of $23.09 for a total value of $50,798.Source: Announcement What is st

Futu NewsMay 3 15:49

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $40

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics with a Buy and raises the price target from $38 to $40.

Analyst UpgradesMay 2 12:33

Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities

Corcept Therapeutics Price Target Raised to $44.00/Share From $42.00 by Truist Securities

Dow JonesMay 2 08:23

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Corcept Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesMay 2 08:23

Earnings Call Summary | Corcept Therapeutics(CORT.US) Q1 2024 Earnings Conference

The following is a summary of the Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript:Financial Performance:Corcept Therapeutics reported Q1 2024 revenues of $146.8 million, a 39

Futu NewsMay 2 08:20 · Conference Call

Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating

Corcept Therapeutics (CORT) has an average rating of buy and price targets ranging from $35 to $61, according to analysts polled by Capital IQ. Price: 26.15, Change: +2.27, Percent Change: +9.51

MT NewswiresMay 2 07:30

Q1 2024 Corcept Therapeutics Inc Earnings Call

Yahoo FinanceMay 2 07:01

Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 1 22:42

Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024

Yahoo FinanceMay 1 16:50

Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.

Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.

BenzingaMay 1 15:32

Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est

Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est

BenzingaMay 1 15:19

Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, Vs. Street Est of $0.22

04:12 PM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22

MT NewswiresMay 1 15:12

Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT

Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT

Dow JonesMay 1 15:08

Corcept Therapeutics 1Q EPS 25c >CORT

Corcept Therapeutics 1Q EPS 25c >CORT

Dow JonesMay 1 15:05

Press Release: Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a c

Dow JonesMay 1 15:05